Okopień Bogusław, Buldak Lukasz, Bołdys Aleksandra
a Department of Internal Medicine and Clinical Pharmacology, School of Medicine in Katowice , Medical University of Silesia , Katowice , Poland.
Expert Rev Cardiovasc Ther. 2017 Dec;15(12):913-921. doi: 10.1080/14779072.2017.1408410. Epub 2017 Nov 28.
Significant advancements in the treatment of hypercholesterolemia have recently been achieved. However, a considerable level of residual cardiovascular risk still affects patients' outcomes. Atherogenic dyslipidemia is one of the major constituents of residual risk. Fibrates, PPAR alpha agonists, which modify lipid profile and have numerous pleiotropic effects, seem to be drugs of choice in patients with atherogenic dyslipidemia. These drugs are effective both in monotherapy and combined therapy with statins. Areas covered: A review of clinical trials and experimental studies on fibrates and their use in the treatment of lipid disorders has been performed. Expert commentary: Fibrates are an effective and safe group of drugs to treat patients with atherogenic dyslipidemia. In this particular population of patients, they improve cardiovascular outcomes. Benefits of fibrate treatment extend beyond the impact of lipid profile. Significant improvements in carbohydrate metabolism, adipokines levels, thrombosis and inflammation were also noted.
最近，高胆固醇血症的治疗取得了重大进展。然而，相当程度的残余心血管风险仍然影响着患者的预后。致动脉粥样硬化性血脂异常是残余风险的主要组成部分之一。贝特类药物，即过氧化物酶体增殖物激活受体α激动剂，可改善血脂谱并具有多种多效性作用，似乎是致动脉粥样硬化性血脂异常患者的首选药物。这些药物在单药治疗以及与他汀类药物联合治疗中均有效。涵盖领域：对贝特类药物的临床试验和实验研究及其在脂质紊乱治疗中的应用进行了综述。专家评论：贝特类药物是治疗致动脉粥样硬化性血脂异常患者的有效且安全的药物组。在这一特定患者群体中，它们可改善心血管预后。贝特类药物治疗的益处不仅限于对血脂谱的影响。还注意到碳水化合物代谢、脂肪因子水平、血栓形成和炎症方面有显著改善。
